Breaking News, Collaborations & Alliances

FibroBiologics, Charles River Partner to Manufacture Cell-Based Therapies

Charles River will serve as the CDMO to produce the drug products for FibroBiologics’ upcoming clinical trial.

Author Image

By: Charlie Sternberg

Associate Editor

FibroBiologics Inc., a clinical-stage biotechnology company, and Charles River Laboratories, a global drug discovery, development, testing, and manufacturing solutions provider, have established a master services agreement to develop and manufacture FibroBiologics’ therapeutic master cell bank, working cell bank, and fibroblast-based spheroids product, CYWC628, for utilization in a diabetic foot ulcer (DFU) clinical trial slated to begin in 2025.   FibroBiologics is investigating the potential...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters